Of all the options there are in the market, of particular relevance are those that seek to stimulate skin regeneration through the use of growth factors extracted from the patient's own plasma. The use of biologically active growth factors and an autologous fibrin matrix applied locally to damaged areas facilitates cell renewal and improves skin health in a more natural way. This technology, Endoret®(prgf®) technology, also contributes to the treatment of different dermatological complications and accelerates the healing process of chronic ulcers in a short period of time.
The appearance of chronic ulcers is a very common complication in a wide range of pathologies that has a negative impact on the quality of life of the affected patients and leads to situations in which the amputation of the extremity is inevitable. Clinical data prove the safety and effectiveness of Endoret®(prgf®) as a therapeutic treatment to accelerate the healing process of different types of chronic ulcers.
Treatment with Endoret®(prgf®) has lead to spectacular results in tissues damaged by a lack of blood irrigation that require vascular surgery. Likewise, vascular ulcers show significant improvement with this treatment.
Within the general process of ageing, the ageing of skin is not an isolated process, but is part of a general process that includes all organs and systems. However, the importance we currently attach to our physical appearance is growing. This growing aesthetic awareness means that the interest in developing new products to help us improve the appearance of our skin has increased.
The idea of using Endoret®(prgf®) to treat facial ageing is the result of a wide range of basic and clinical observations concerning its beneficial effect after its application to other tissues. The capacity of Endoret®(prgf®) to activate the regeneration of tissues can counteract the degenerative changes that take place in the skin after the third decade of life, improving its tone and plasticity.
This section may describe clearances in countries other than the Unite States, and therefore may contain indications and information that are outside the scope of the FDA-cleared.